HAIER BIOMEDICAL(SH:688139) Chang Jiang Shang Bao·2025-11-18 23:45Core Viewpoint - Haier Biomedical plans to cancel 1.4596 million repurchased shares to optimize its equity structure, reflecting its commitment to shareholder returns through a "repurchase + dividend" mechanism since its IPO in 2019 [1][2] Share Repurchase and Capital Reduction - The cancellation of shares will reduce the company's registered capital by approximately 1.46 million yuan, representing 0.46% of the total share capital, which will decrease from 318 million shares to 316 million shares [2] - This action is part of the company's ongoing efforts to fulfill its repurchase commitments and enhance its equity structure, signaling confidence in its intrinsic value [2] Financial Performance - Haier Biomedical has shown steady growth since its establishment, with revenue increasing from 1.013 billion yuan in 2019 to 2.284 billion yuan in 2024, a growth rate of 125.47%, and net profit rising from 182 million yuan to 367 million yuan, a growth rate of 101.65% [3] - However, in the first three quarters of 2025, the company faced pressure, with revenue of 1.761 billion yuan, a year-on-year decline of 1.17%, and net profit of 198 million yuan, a decrease of 35.83% [3] - The third quarter of 2025 showed signs of recovery, with revenue of 566 million yuan, a year-on-year increase of 1.24% and a quarter-on-quarter increase of 11.68%, and net profit reaching 55.65 million yuan [3][4] R&D Investment and Technological Development - Over the past five years, Haier Biomedical has invested a total of 1.398 billion yuan in R&D, with annual expenditures ranging from 236 million yuan to 321 million yuan [5] - The company has established a multi-layer AI foundation and has led or participated in drafting 64 national and industry standards, with 32 recognized as internationally leading [5]